[Recommendations for the administration of conventional and new antithrombotic agents from the perspective of anesthesiology].
Neuraxial blockade confers benefits to surgical patients not only due to the high analgesic quality but also through a reduction in postoperative complications, such as respiratory insufficiency and a shortening of postoperative paralytic ileus. In orthopedic surgery peripheral and neuraxial blockades are extensively used to enhance postoperative mobilization. The most serious complication of neuraxial blockade is spinal epidural hematoma, which may lead to permanent paraplegia if left untreated. The risk is enhanced in patients receiving thromboembolism prophylaxis. Most national societies have issued guidelines with specific time intervals between application of antithrombotic drugs and subsequent neuraxial blockade to minimize this risk. From the viewpoint of an anesthesiologist it is preferable to start with chemical thromboembolism prophylaxis postoperatively as opposed to preoperatively, to administer all drugs in the evening and to limit the number of available drugs at each site. The safety of neuraxial blockade in the presence of the new oral anticoagulant rivaroxaban is currently unknown due to limited experience and dabigatran is considered contraindicated with indwelling epidural catheters according to the manufacturer.
Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie, Klinikum Harlaching, Städtisches Klinikum München GmbH, Sanatoriumsplatz 2, 81545, München, Deutschland. wiebke.gogarten@klinikum-muenchen.de
W
W
Gogarten
K
K
Hoffmann
H
H
Van Aken
D000779:Anesthetics, Local / Q000008:administration & dosage*; D000925:Anticoagulants / Q000008:administration & dosage*; D004347:Drug Interactions; D006801:Humans; D011183:Postoperative Complications / Q000517:prevention & control*; D013923:Thromboembolism / Q000209:etiology* / Q000517:prevention & control*; D014947:Wounds and Injuries / Q000150:complications* / Q000601:surgery*
D000779:Anesthetics, Local; D000925:Anticoagulants